Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Dec 9, 2020
Date Accepted: May 17, 2021
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Machine Learning-Based Predictive Analytics Marketed as Improving Health Care Efficiency: What Types of Products and Who is Marketing Them?
ABSTRACT
Background:
Considerable effort is devoted to development of artificial intelligence, including machine learning-based predictive analytics (MLPA), for use in health care settings. Growth of MLPA could be fueled by payment reforms that hold health care organizations responsible for providing high quality, cost-effective care. Policy analysts, ethicists and computer scientists have identified unique ethical and regulatory challenges from MLPA in health care. However, little is known about the types of MLPA health care products available on the market today or what their stated goals are.
Objective:
To better characterize available products, we identified and characterized claims about products currently in use in U.S. health care settings that are marketed as tools to improve health care efficiency by improving quality of care while reducing costs.
Methods:
We conducted systematic database searches of relevant business news and academic research to identify MLPA products for health care efficiency that met our inclusion and exclusion criteria. We used content analysis to generate MLPA product categories and to characterize the organizations marketing the products.
Results:
We identified 106 products and characterized them based on publicly available information in terms of the types of predictions made, and the size, type, and clinical training of the leadership of the companies marketing them. We identified five categories of predictions made by MLPA products based on the publicly available product marketing materials: disease onset and progression, treatment, cost and utilization, admissions and readmissions, and decompensation and adverse events.
Conclusions:
Our findings provide a foundational reference to inform analysis of the specific ethical and regulatory challenges arising from the use of MLPA to improve healthcare efficiency.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.